ArticleCell death & disease2026
USP24-dependent STAT2 stabilization mediates physiologic and pathologic bone formation.
Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Osteoblast development must be precisely regulated, as insufficient bone formation results in low bone mass and skeletal fragility, whereas excessive osteogenesis drives heterotopic ossification (HO), the ectopic formation of bone in soft tissues. Here, we identify the deubiquitinating enzyme ubiquitin-specific peptidase 24 (USP24) as a key regulator of both physiological and pathological ossification. USP24 is highly expressed in skeletal tissues, where it promotes osteoblast development by stabilizing STAT2 through deubiquitination. Loss of USP24 reduces osteoblast differentiation and bone formation, an effect mirrored by STAT2 deficiency. Beyond physiologic bone, USP24 and STAT2 are also strongly expressed in heterotopic bones from patients with HO. In a fibrodysplasia ossificans progressiva (FOP) mouse model, recombinant adeno-associated virus (rAAV)-mediated silencing of Usp24 markedly diminished HO pathogenesis and reduced STAT2 protein levels in HO lesions. Consistently, USP24 deficiency attenuated activin A-induced bone morphogenetic protein (BMP) signaling and osteogenesis, with comparable effects observed upon Stat2 silencing. Together, these findings uncover a previously unrecognized role for USP24-STAT2 signaling in osteoblast differentiation and HO, highlighting bone-targeted USP24-STAT2 inhibition as a potential therapeutic strategy for pathologic bone formation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.